NCT00826930View on ClinicalTrials.gov

Trans Sodium Crocetinate (TSC) Study of Intra-tumoral Oxygen Concentration, Safety, and Pharmacokinetics in Patients With High Grade Glioma

PHASE1TerminatedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

March 31, 2009

Primary Completion Date

May 31, 2009

Study Completion Date

May 31, 2009

Conditions
High Grade Glioma
Interventions
DRUG

Trans Sodium Crocetinate (TSC)

Single bolus intravenous administration in a superficial vein of the arm over a period of up to 2 minutes.

Trial Locations (1)

21205

Johns Hopkins Medical Institute/Johns Hopkins Hospital, Baltimore

Sponsors
All Listed Sponsors
lead

Diffusion Pharmaceuticals Inc

INDUSTRY